Adynxx (FRA:HL1C) ROCE % : 0.00% (As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adynxx's annualized ROCE % for the quarter that ended in Sep. 2019 was 0.00%.

Adynxx ROCE % Historical Data

The historical data trend for Adynxx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx ROCE % Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

ROCE %

Get a 7-Day Free Trial

-132.85

-53.06

-55.56

-17.46

-44.77

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
ROCE %	Get a 7-Day Free Trial															-38.96	-62.37	-45.22	-4,620.93	-

Adynxx ROCE % Calculation

Adynxx's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	-4.655	/	( ( (27.834 - 14.339)	+	(8.508 - 1.21) )	/ 2 )
	=	-4.655	/	( (13.495	+	7.298)	/ 2 )
	=	-4.655	/	10.3965
	=	-44.77 %

Adynxx's ROCE % of for the quarter that ended in Sep. 2019 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2019 )		(Q: Jun. 2019 )		(Q: Sep. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2019 )		(Q: Jun. 2019 )		(Q: Sep. 2019 )
	=	-6.072	/	( ( (2.392 - 10.143)	+	(2.955 - 12.528) )	/ 2 )
	=	-6.072	/	( ( -7.751	+	-9.573 )	/ 2 )
	=	-6.072	/	-8.662
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

Adynxx (FRA:HL1C) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adynxx ROCE % Related Terms

Thank you for viewing the detailed overview of Adynxx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (FRA:HL1C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines